You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameBezitramide
Accession NumberDB01459
TypeSmall Molecule
GroupsExperimental, Illicit, Withdrawn
DescriptionBezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [1], and marketed under the name Burgodin(R). After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. In the United States Bezitramide was never been approved for clinical use. It is presently an illegal substance classified under Schedule II of the Controlled Substances Act. [wiki]
Structure
Thumb
Synonyms
1-[1-(3-Cyano-3,3-diphenylpropyl)-4-piperidinyl]-1,3-dihydro-3-(1-oxopropyl)-2H-benzimidazol-2-one
External Identifiers
  • R 4845
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Burgodin Janssen Pharmceutica
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3KXW0Y310I
CAS number15301-48-1
WeightAverage: 492.6114
Monoisotopic: 492.252526288
Chemical FormulaC31H32N4O2
InChI KeyFLKWNFFCSSJANB-UHFFFAOYSA-N
InChI
InChI=1S/C31H32N4O2/c1-2-29(36)35-28-16-10-9-15-27(28)34(30(35)37)26-17-20-33(21-18-26)22-19-31(23-32,24-11-5-3-6-12-24)25-13-7-4-8-14-25/h3-16,26H,2,17-22H2,1H3
IUPAC Name
4-[4-(2-oxo-3-propanoyl-2,3-dihydro-1H-1,3-benzodiazol-1-yl)piperidin-1-yl]-2,2-diphenylbutanenitrile
SMILES
CCC(=O)N1C(=O)N(C2CCN(CCC(C#N)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C2=CC=CC=C12
Pharmacology
IndicationA narcotic analgesic once used for the treatment of severe chronic pain. [1]
Structured Indications Not Available
PharmacodynamicsBezitramide acts in the body to relieve pain with a potency 20 times that of methadone [1]. Its duration of action is relatively long, lasting up to 12 hours post oral administration, after the achievement of steady state. Its onset of action is slow, with a peak in analgesic effect noted between 2.5-3.5 hours after dosing. It is noted to illicit a strong antitussive effect, which could be of benefit to patients with bronchial carcinoma.
Mechanism of action
Related Articles
AbsorptionBezitramide has poor water solubility, thus administration is restricted to the oral route. [1]
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Bezitramide is a prodrug which undergoes rapid hydrolysis of a proprionyl-group to form the major metabolite, R-4618. R-4618 has analgesic properties similar to the parent compound.[1] Metabolism occurs in the gastrointestinal tract under both acidic and alkaline conditions [1].

Route of eliminationLess than 0.3% of the dose was excreted unchanged in the urine. High concentrations in feces suggested incomplete absorption of biliary excretion. Experiments in rats demonstrated extensive (up to 70%) biliary excretion, and less than 3% urinary excretion. [1]
Half life11-24h. [1]
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit
AcepromazineAcepromazine may increase the hypotensive activities of Bezitramide.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bezitramide.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Bezitramide.Approved
AlimemazineAlimemazine may increase the hypotensive activities of Bezitramide.Approved, Vet Approved
AlvimopanThe risk or severity of adverse effects can be increased when Bezitramide is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Amiloride.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Bezitramide which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmphetamineAmphetamine may increase the analgesic activities of Bezitramide.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Bezitramide.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Bezitramide.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Bezitramide.Approved, Vet Approved
AzosemideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Azosemide.Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Bezitramide.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Bendroflumethiazide.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Bezitramide.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Bezitramide.Approved, Illicit
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Bezitramide.Approved
BL-1020BL-1020 may increase the hypotensive activities of Bezitramide.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Bumetanide.Approved
BuprenorphineBuprenorphine may decrease the analgesic activities of Bezitramide.Approved, Illicit, Investigational, Vet Approved
ButorphanolButorphanol may decrease the analgesic activities of Bezitramide.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Bezitramide is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Canrenone.Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Bezitramide.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Bezitramide.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bezitramide.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorthalidone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Bezitramide is combined with Cicletanine.Investigational
CitalopramBezitramide may increase the serotonergic activities of Citalopram.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Bezitramide is combined with Conivaptan.Approved, Investigational
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Bezitramide.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Cyclothiazide.Approved
DapoxetineBezitramide may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Bezitramide.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Bezitramide.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.Approved
DesvenlafaxineBezitramide may increase the serotonergic activities of Desvenlafaxine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Bezitramide.Withdrawn
DextroamphetamineDextroamphetamine may increase the analgesic activities of Bezitramide.Approved, Illicit
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Bezitramide.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Bezitramide.Approved, Illicit
DrospirenoneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Drospirenone.Approved
DuloxetineBezitramide may increase the serotonergic activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Bezitramide is combined with Efonidipine.Approved
EluxadolineBezitramide may increase the constipating activities of Eluxadoline.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Eplerenone.Approved
EscitalopramBezitramide may increase the serotonergic activities of Escitalopram.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Bezitramide is combined with Etacrynic acid.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Bezitramide.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Ethoxzolamide.Withdrawn
EtoperidoneBezitramide may increase the serotonergic activities of Etoperidone.Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Bezitramide.Approved
FluoxetineBezitramide may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bezitramide.Approved
FluvoxamineBezitramide may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Furosemide.Approved, Vet Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Bezitramide.Approved
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Bezitramide.Approved, Investigational, Vet Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Bezitramide.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Bezitramide.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Hydroflumethiazide.Approved
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Bezitramide.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Bezitramide.Approved
IndalpineBezitramide may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Indapamide.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Bezitramide.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Isosorbide.Approved
KW-3902The risk or severity of adverse effects can be increased when Bezitramide is combined with KW-3902.Investigational
LevomilnacipranBezitramide may increase the serotonergic activities of Levomilnacipran.Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Bezitramide.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Bezitramide is combined with Mannitol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bezitramide.Approved
MephedroneMephedrone may increase the analgesic activities of Bezitramide.Investigational
MephentermineMephentermine may increase the analgesic activities of Bezitramide.Approved
MersalylThe risk or severity of adverse effects can be increased when Bezitramide is combined with Mersalyl.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bezitramide.Approved
MethamphetamineMethamphetamine may increase the analgesic activities of Bezitramide.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Bezitramide.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Methazolamide.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bezitramide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bezitramide.Investigational
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Bezitramide.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Metolazone.Approved
MilnacipranBezitramide may increase the serotonergic activities of Milnacipran.Approved
MMDAMMDA may increase the analgesic activities of Bezitramide.Experimental, Illicit
MoricizineMoricizine may increase the hypotensive activities of Bezitramide.Approved, Withdrawn
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Bezitramide.Vet Approved
NalbuphineNalbuphine may decrease the analgesic activities of Bezitramide.Approved
NaltrexoneThe therapeutic efficacy of Bezitramide can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneBezitramide may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Bezitramide.Investigational
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Bezitramide.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Bezitramide.Approved, Investigational
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Bezitramide.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Bezitramide.Approved
ParoxetineBezitramide may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Bezitramide.Approved
PentazocinePentazocine may decrease the analgesic activities of Bezitramide.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Bezitramide.Approved
PerazinePerazine may increase the hypotensive activities of Bezitramide.Investigational
PerphenazinePerphenazine may increase the hypotensive activities of Bezitramide.Approved
PhenterminePhentermine may increase the analgesic activities of Bezitramide.Approved, Illicit
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Bezitramide.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Bezitramide.Approved
PiretanideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Piretanide.Experimental
PolythiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Polythiazide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium Citrate.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bezitramide.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Bezitramide.Approved
PromazinePromazine may increase the hypotensive activities of Bezitramide.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bezitramide.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Bezitramide.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bezitramide.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Bezitramide.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Bezitramide.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Bezitramide.Approved
RamosetronBezitramide may increase the constipating activities of Ramosetron.Approved
RitobegronRitobegron may increase the analgesic activities of Bezitramide.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Bezitramide is combined with Rolofylline.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bezitramide.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Bezitramide.Approved
SertralineBezitramide may increase the serotonergic activities of Sertraline.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Bezitramide.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Spironolactone.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Bezitramide.Approved
TheobromineThe risk or severity of adverse effects can be increased when Bezitramide is combined with Theobromine.Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bezitramide.Withdrawn
ThioridazineThioridazine may increase the hypotensive activities of Bezitramide.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Bezitramide is combined with Ticrynafen.Withdrawn
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Bezitramide.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Bezitramide.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Bezitramide is combined with Tolvaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Torasemide.Approved
TriamtereneThe risk or severity of adverse effects can be increased when Bezitramide is combined with Triamterene.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bezitramide.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bezitramide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Bezitramide.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Bezitramide.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Bezitramide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Bezitramide.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Bezitramide.Approved
UlaritideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Bezitramide.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Bezitramide.Approved
VenlafaxineBezitramide may increase the serotonergic activities of Venlafaxine.Approved
ZimelidineBezitramide may increase the serotonergic activities of Zimelidine.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Meijer DK, Hovinga G, Versluis A, Broring J, van Aken K, Moolenaar F, Wesseling H: Pharmacokinetics of the oral narcotic analgesic bezitramide and preliminary observations on its effect on experimentally induced pain. Eur J Clin Pharmacol. 1984;27(5):615-8. [PubMed:6519169 ]
External Links
ATC CodesN02AC05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9787
Caco-2 permeable-0.5631
P-glycoprotein substrateSubstrate0.6446
P-glycoprotein inhibitor IInhibitor0.8347
P-glycoprotein inhibitor IINon-inhibitor0.6466
Renal organic cation transporterNon-inhibitor0.518
CYP450 2C9 substrateNon-substrate0.7483
CYP450 2D6 substrateNon-substrate0.6835
CYP450 3A4 substrateSubstrate0.6644
CYP450 1A2 substrateNon-inhibitor0.9217
CYP450 2C9 inhibitorNon-inhibitor0.5586
CYP450 2D6 inhibitorNon-inhibitor0.7687
CYP450 2C19 inhibitorNon-inhibitor0.8888
CYP450 3A4 inhibitorInhibitor0.584
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6976
Ames testNon AMES toxic0.569
CarcinogenicityNon-carcinogens0.8409
BiodegradationNot ready biodegradable0.9939
Rat acute toxicity3.5117 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5527
hERG inhibition (predictor II)Inhibitor0.6899
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point145-149 °CPhysProp
water solubilityPoor water solubility Meijer, D. K. F., et al. "Pharmacokinetics of the oral narcotic analgesic bezitramide and preliminary observations on its effect on experimentally induced pain." European journal of clinical pharmacology 27.5 (1984): 615-618.
logP4.80SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0067 mg/mLALOGPS
logP4.35ALOGPS
logP4.79ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)8.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area67.65 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity155.25 m3·mol-1ChemAxon
Polarizability55.58 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylacetonitriles. These are cyclic aromatic compounds containing a diphenylacetonitrile moiety, which consists of a diphenylmethane linked to and acetonitrile to form 2,2-diphenylacetonitrile.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylacetonitriles
Direct ParentDiphenylacetonitriles
Alternative Parents
Substituents
  • Diphenylacetonitrile
  • Diphenylmethane
  • Phenylpropylamine
  • Benzyl-cyanide
  • Benzimidazole
  • Aralkylamine
  • 4-aminopiperidine
  • Piperidine
  • N-substituted imidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23